on B.R.A.I.N. Biotechnology Research And Information Network AG (ETR:DE000520)
BRAIN Biotech Reports Q1 Results and SolasCure's Clinical Milestone
BRAIN Biotech AG released its first quarter results for the fiscal year 2025/26, recording a revenue of €11.9 million, a 9.0% decline from the previous year. Despite this, adjusted EBITDA improved to €0.3 million, owing to a strong performance by the BRAINBioIncubator segment, which saw a €1.0 million milestone income.
SolasCure, a company held at 35% by BRAIN Biotech, achieved a significant clinical breakthrough with its Aurase Wound Gel, demonstrating marked success in treating chronic wounds. The gel presented 22 times better debridement and 7 times faster healing than current standards. SolasCure now plans a fundraising for its next clinical trial phase.
BRAIN Biotech's core segment, BRAINBiocatalysts, experienced a revenue dip, attributed to lower sales in baking enzymes and beverages. However, future sequential growth is expected. Overall, the company maintains its sales outlook for the fiscal year.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all B.R.A.I.N. Biotechnology Research And Information Network AG news